Feedback Regulatory News (FDBK)

Feedback plc

Bleepa selected for Digitalhealth.London 2020 Accelerator Programme

· 12 month programme to support the pioneering of digital innovations by the NHS

· Dedicated support by NHS Expert to showcase innovations in health facilities

· Improves market access and NHS navigation to scale digital products across the health and care sector in London

London, 10 November 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Bleepa has been selected for DigitalHealth.London's 2020 12 month accelerator programme to promote innovative technologies to London NHS hospitals.

DigitalHealth.London

DigitalHealth.London's Accelerator programme aims to speed up the adoption of technology within London's NHS, relieving high pressure on services and empowering patients to manage their health.

Now in its fifth consecutive year, the DigitalHealth.London Accelerator works with up to 20 high potential SMEs over a 12-month period, giving bespoke support and advice, a programme of expert-led workshops and events, and brokering meaningful connections between innovators and NHS organisations with specific challenges. Each SME is assigned an NHS Navigator, an experienced professional from the NHS with the expertise to share advice on products in development, NHS navigation and business models.

Dr Tom Oakley, CEO of Feedback, commented:

"DigitalHealth.London is a targeted accelerator for London hospitals with a focus to scan the horizon for the very best of new innovative healthcare technologies, which it then showcases to London-based hospitals. It has an extremely rigorous selection process and we are delighted that Bleepa has been chosen as part of the 2020 offering. For us, this is an important opportunity to really get in front of the London hospital network to show them what Bleepa can do, how it can revolutionise their imaging communications and ultimately, why they should choose Bleepa."

-Ends-

Enquiries:

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

DigitalHealth.London

DigitalHealth.London is helping health tech entrepreneurs and healthcare professionals turn the idea of digital innovation into tangible improvements for staff and patients. 

Our initiatives bring together health and care stakeholders across London to collaborate and solve some of the biggest challenges in the NHS. 

DigitalHealth.London is a collaborative programme delivered by MedCity, and London's three Academic Health Science Networks - UCL Partners, Imperial College Health Partners and the Health Innovation Network. 

It is supported by NHS England (London) and the Mayor's Office. The DigitalHealth.London Accelerator is supported by the additional partner, CW+, and is part-funded through the European Regional Development Fund.

https://digitalhealth.london/about/

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.